Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
1997-12-30
2003-02-11
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S045000, C424S450000, C514S053000, C514S958000, C536S119000
Reexamination Certificate
active
06517860
ABSTRACT:
TECHNICAL FIELD
This invention relates to compositions for use in delivery of bioactive agents to mucosal surfaces. The compositions provide increased bioavailability of the bioactive agents, particularly hydrophobic bioactive agents.
BACKGROUND ART
Oral delivery is the potentially most attractive route of bioactive agent delivery as it involves non-invasive techniques and enjoys a high patient compliance. The main drawback with oral delivery is the poor bioavailability of the vast majority of molecules via the gastrointestinal mucosa. Bioavailability refers to both the true rate and total amount (extent) of drug that reaches the general circulation from an administered dosage form.
Bioavailability is limited mainly by the dissolution and stability of the macromolecule in the milieu at the mucosal surface and the transport of the macromolecule across this surface (during absorption). While the former favours hydrophilic bioactive agents with increased dissolution in aqueous body fluids at the mucosal surface, the latter favours hydrophobic molecules which need to cross the apolar lipid bilayer of the cell membrane in order to enter the bloodstream. Bioavailability is also complicated by the non-aqueous behaviour of some mucosal surface milieus such as the amphipathic behaviour of lung surfactant at the pulmonary mucosal surface.
Hydrophobic bioactive agents in particular suffer from drawbacks in dosage formulation and bioavailability. Dosage formulations are often liquid, with the use of hydrophobic solvent such as oils or ethanol. Frequently, detergents are added to hydrophobic bioactive agent suspensions to enable formation of emulsions. Emulsions can improve bioavailability by placing the bioactive agent in suspension or a discontinuous array of droplets. Bioavailability from emulsion formulations is still limited. Intestinal mobility often moves these preparations past the absorption window in the proximal small bowel before these droplets or suspended particles are reduced in size sufficiently to be absorbed. Moreover, the manufacture and storage of emulsions is problematic due to phase separation and partitioning. A number of hydrophobic bioactive agents such as Cyclosporine A (CyA), Cephalosporins, amphotericins, griseofulvins, and other antifungals and antibiotics, taxols and vitamins would be improved by the formulation of dosage forms with increased bioavailability. The wide variety of bioactive agents includes, but is not limited to, those listed in Table 1.
TABLE 1
Antiasthma
Antiarrhythmic
Tranquilizers
metaproterenol
propanolol
chlorpromazine
aminophylline
etanolol
benzodiazepine
theophylline
verapamil
butyrophenomes
terbutaline
captopril
hydroxyzines
Tegretol
isosorbide
meprobamate
ephedrine
phenothiazines
isoproterenol
reserpine
adrenaline
thioxanthines
norepinephrine
Cardiac glycosides
Hormones
Steroids
digitalis
antidiuretic
prednisone
digitoxin
corticosteroids
triamcinolone
lanatoside C
testosterone
hydrocortisone
digoxin
estrogen
dexamethasone
thyroid
betamethasone
growth
prednisolone
ACTH
progesterone
gonadotropin
mineralocorticoid
Antihypertensives
Antidiabetic
Antihistamines
apresoline
Diabenese
pyribenzamine
etanolol
insuiin
chlorpheniramine
diphenhydramine
Antiparasitic
Anticancer
Sedatives & Analgesic
praziquantel
azathioprine
morphine
metronidazole
bleomycin
dilaudid
pentamidine
byclophosphamide
codeine
adriamycin
codeine-like synthetics
daunorubicin
Demerol
vincristine
oxymorphone
Phenobarbital
barbiturates
Antibiotic
Immunotherapies
Vaccines
amphotericins
interferon
influenza
penicillin
interleukin-2
respiratory syncytial
tetracycline
monoclonal antibodies
virus
erythromycin
gammaglobulin
Hemophilus influenza
cephalothin
vaccine
imipenem
Antifungal
Antiviral
cefofaxime
amphotericin B
acyclovir and derivatives
carbenicillin
myconazole
Winthrop-51711
vancomycin
muramyl dipeptide
ribavirin
gentamycin
clotrimazole
rimantadine/amantadine
tobramycin
Antihypotensives
azidothymidine &
piperacillin
dopamine
derivatives
moxalactam
dextroamphetamine
adenine arabinoside
amoxicillin
amidine-type protease
ampicillin
inhibitors
cefazolin
Other
cefadroxil
receptor agonists and
cefoxitin
antagonists
other aminoglycosides
other cephalosporins
One of the most frequently used hydrophobic bioactive agents, CyA is virtually insoluble in aqueous solvents and soluble in ethanol or fixed oils. The two most common dosage forms of CyA are administered as an oil formulation that must be formed into a microemulsion prior to absorption. These two formulations, Neoral® and Sandimmune® essentially differ in their bioavailability in that the former forms microemulsions more efficiently and this formulation shows significantly better bioavailability. GB Patent No. 2,257,359A. Neither formulation allows for a dry formulation such as a tablet or powder which would be of considerable benefit with respect to manufacture and storage of the drug.
CyA is of particular importance as it is being used not only as an immunosuppressant in transplant patients, but also as a treatment for asthma, dermatitis and arthritis. EP 577,544; EP 504,760 Tominaga et al. (1995)
Gen. Pharmac.
26:353-356; and Arima et al. (1994)
Jpn. J Allergol.
43:1316-1325. Dosage forms for treating asthma, other pulmonary conditions or for by-inhalation administration are most often in the form of aerosols of a fine mist of aqueous droplets. Several dosage forms and devices for by-inhalation delivery of hydrophobic bioactive agents have been described. These include small particle aerosol liposomes, aerosolized ethanol; and ultrasonic nebulizers. EP 267,050; EP 577,544; and Arima et al. (1994). More recently, the pulmonary administration of dry powders, driven by the need to eliminate aerosol propellants, has seen the development of many dry powder inhalers.
A variety of formulations have been provided for administration in aerosolized form to mucosal surfaces, particularly “by-inhalation” (nasopharyngeal and pulmonary). Compositions for by-inhalation pharmaceutical administration generally comprise a liquid formulation of the bioactive agent and a device for delivering the liquid in aerosolized form. U.S. Pat. No. 5,011,678 describes suitable compositions containing a pharmaceutically active substance, a biocompatible amphiphilic steroid and a biocompatible (hydro/fluor) carbon propellant. U.S. Pat. No. 5,006,343 describes suitable compositions containing liposomes, pharmaceutically active substances and an amount of alveolar surfactant protein effective to enhance transport of the liposomes across a pulmonary surface.
One drawback to the use of aerosolized formulations is that maintenance of pharmaceutical agents in aqueous suspensions or solutions can lead to aggregation and loss of activity and bioavailability. The loss of activity can be partially prevented by refrigeration; however, this limits the utility of these formulations. This is particularly true in the case of peptides and hormones. For instance, synthetic gonadotropin releasing hormone analogs, such as the agonist nafarelin or the antagonist ganirelex, are designed for high potency, increased hydrophobicity and membrane binding. The compounds have sufficient hydrophobic character to aggregate in aqueous solution and to form an ordered structure that increases in viscosity with time. Thus, bioavailability in nasal or pulmonary formulations can be prohibitively low.
DISCLOSURE OF THE INVENTION
The invention encompasses methods of making compositions with increased bioavailability for mucosal delivery of bioactive agents. The invention further comprises the compositions obtained thereby. In one embodiment, the compositions contain bioactive agents and hydrophobically-derivatized (substituted) carbohydrates (HDCS) in powder form. In another embodiment, the dosage forms contain bioactive agents, HDCs and surfactants in powder form. The compositions form solid solutions, suspensions or emulsions of bioactive agents, with or without modifiers and/or other additives, in an HDC glass.
The invention also encompasses methods of making compositions of suspensions
Colaco Camilo
Kampinga Jaap
Roser Bruce J.
Sanderson Ian
Channavajjala Lakshmi
Page Thurman K.
Quadrant Holdings Cambridge Ltd.
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Methods and compositions for improved bioavailability of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for improved bioavailability of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for improved bioavailability of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3139886